The results for the two RWSs [ 1 , 33 ] with BCVA change measured at 6 months showed a numerical trend of higher improvement for aflibercept compared with ranibizumab, but the difference was not statistically significant ( n = 84, MD 5.09, 95% CI − 16.19 to 26.37, P = 0.64) (Fig. 2 ), similar to the subgroup of patients with non-ischemic CRVO (Supplementary Materials Table S10 ).
← all excerpts
Efficacy, Safety, and Treatment Burden of Aflibercept 2 mg and Ranibizumab in Retinal Vein Occlusion: A Systematic Review and Meta-analysis.
1
—
—